<DrugInformationSummary id="CDR0000746946"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Ado-trastuzumab emtansine is a type of targeted therapy drug called an antibodyâ€“drug conjugate. It is a monoclonal antibody chemically linked to a chemotherapy drug. The antibody portion binds to HER2, a protein found in high levels on some cancer cells and causes them to grow, and delivers a drug called emtansine (or DM-1), a microtubule inhibitor, to those cells, killing them. Ado-trastuzumab emtansine may also stimulate the immune system to kill cancer cells.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/ado-trastuzumab-emtansine">Ado-Trastuzumab Emtansine</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000564399">ado-trastuzumab emtansine</TerminologyLink><GlossaryLink ref="CDR0000747093">ado-trastuzumab emtansine</GlossaryLink><USBrandNames><USBrandName>Kadcyla</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>A-doh-tras-TOO-zoo-mab   em-TAN-seen</TermPronunciation><MediaLink ref="CDR0000749859" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000749858" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Ado-Trastuzumab Emtansine</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f3c1f4-0fc8-4804-a9e3-04cf25dd302e&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Ado-trastuzumab emtansine
         is approved 
         to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000444971" dictionary="Cancer.gov" audience="Patient">Breast cancer</GlossaryTermRef></Strong> that is <GlossaryTermRef href="CDR0000737998" dictionary="Cancer.gov" audience="Patient">HER2 positive</GlossaryTermRef> and has already been treated with a <GlossaryTermRef href="CDR0000046138" dictionary="Cancer.gov" audience="Patient">taxane</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045439" dictionary="Cancer.gov" audience="Patient">trastuzumab</GlossaryTermRef>. It is used:<ItemizedList Style="bullet" id="_5"><ListItem>as <GlossaryTermRef href="CDR0000467826" dictionary="Cancer.gov" audience="Patient">adjuvant therapy</GlossaryTermRef> in patients with  <GlossaryTermRef href="CDR0000446564" dictionary="Cancer.gov" audience="Patient">early-stage breast cancer</GlossaryTermRef>. It is used  in these patients when  <GlossaryTermRef href="CDR0000537695" dictionary="Cancer.gov" audience="Patient">invasive breast cancer</GlossaryTermRef>  is found in the tissue removed during surgery.</ListItem><ListItem>in patients with <GlossaryTermRef href="CDR0000044058" dictionary="Cancer.gov" audience="Patient">metastatic</GlossaryTermRef> breast cancer. It is also used in these patients if the cancer <GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">recurs</GlossaryTermRef> (comes back) after adjuvant therapy.</ListItem> </ItemizedList></ListItem>
   
   </ItemizedList>
  
 <Para id="_4">Ado-trastuzumab emtansine
         is also being studied in the treatment of other types of
         cancer.</Para></Section><Section id="_About"><Title>More About Ado-Trastuzumab Emtansine</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/564399">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.27">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a613031.html">Ado-Trastuzumab Emtansine</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.28"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.29">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C82492">Find Clinical Trials for Ado-trastuzumab Emtansine</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2013-03-13</DateFirstPublished><DateLastModified>2024-12-20</DateLastModified></DrugInformationSummary>
